---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024303"
form_type: "8-K"
ticker: "SIGY"
cik: "0001642159"
company_name: "Sigyn Therapeutics, Inc."
filed_at: "2025-08-15T23:59:59+00:00"
generated_at: "2026-05-17T12:25:42.380836+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Three directors resign after D&O insurance lapse; $550K convertible note issued

## Summary
- Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.
- D&O insurance policy expired Aug 4, 2025; no replacement in place; company evaluating alternatives.
- Entered agreement with Lambda Venture Partners for up to $550K principal, $500K funding; first tranche $110K/$100K.
- Notes bear 8% interest, one-year term, convertible at 35% discount to lowest traded price in prior 10 days.
- No warrants issued; securities sold under Section 4(a)(2) exemption.

## SEC filing metadata
- accession: 0001641172-25-024303
- form_type: 8-K
- ticker: SIGY
- cik: 0001642159
- company_name: Sigyn Therapeutics, Inc.
- filed_at: 2025-08-15T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642159/000164117225024303/0001641172-25-024303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642159/000164117225024303/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024303
- JSON: https://secwatch.observer/filing/0001641172-25-024303.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.